NEW YORK (GenomeWeb News) – Greiner Bio-One has licensed Invitrogen’s deoxyuridine triphosphate technology for use in a PCR-based HPV test and in DNA array products, the companies said today.
Greiner Bio-One said it will use dUTP in place of deoxythymidine triphosphate to prevent false positives during PCR by reducing sample contamination.
The company said the use of dUTP will improve the reliability of its PapilloCheck HPV test and its DNA-array CytoCheck products. Greiner Bio-One will begin offering product kits for PapilloCheck with dUTP in June, and plans to offer dUTP-based kits for CytoCheck this fall.
Financial terms of the agreement were not released.